Mifepristone (RU-486)

Mifepristone (RU-486) is an antagonist of Progesterone Receptor and Estrogen/Progesterone Receptors used in studies of Apoptosis and Autophagy and related signaling programs. It is especially relevant in apoptosis, autophagy, and cancer models, where defined compound exposure can be linked to caspase-associated cell-death signaling and survival decisions and autophagic flux, lysosomal turnover, and stress adaptation.

By blocking Progesterone Receptor and Estrogen/Progesterone Receptors, Mifepristone (RU-486) can be used to examine caspase-associated cell-death signaling and survival decisions and autophagic flux, lysosomal turnover, and stress adaptation. The nuclear receptor annotation adds relevance to reporter-gene, receptor-binding, and transcriptional assays, together with downstream-response mapping in the same experimental setting. In apoptosis, autophagy, and cancer models, these readouts can be combined with viability, reporter, localization, biochemical conversion, or morphology endpoints to refine experimental interpretation.

Research Applications

• Target-focused assays involving Progesterone Receptor and Estrogen/Progesterone Receptors
• Pathway perturbation studies connected to Apoptosis and Autophagy and related signaling programs
• Receptor-blockade and ligand-competition studies
• Reporter-gene, receptor-binding, and transcriptional assays

Overall, Mifepristone (RU-486) is appropriate when a defined chemical perturbant is needed to connect Progesterone Receptor and Estrogen/Progesterone Receptors with measurable biochemical, transcriptional, electrophysiological, imaging, or phenotypic readouts in apoptosis, autophagy, and cancer models. This profile is suited to mechanistic follow-up, comparative profiling, and assay optimization under defined exposure conditions.